DURHAM, N.C., Feb. 7, 2014 /PRNewswire/ -- Argos Therapeutics, Inc. today announced the pricing of its initial public offering of 5,625,000 shares of common stock at a public offering price of $8.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Argos. In addition, the underwriters have an option for a period of 30 days to purchase up to 843,750 additional shares of common stock from Argos at the public offering price, less the underwriting discount. Argos' common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the ticker symbol "ARGS" on February 7, 2014.
Piper Jaffray & Co., Stifel, Nicolaus & Company, Incorporated and JMP Securities LLC are acting as book-running managers for the offering. Needham & Company, LLC is acting as co-manager.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission onFebruary 6, 2014.
The offering is being made only by means of a prospectus, copies of which may be obtained from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone: (800) 747-3924 or by email: prospectuspjc.com; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104 or by telephone: (415) 364-2720; or JMP Securities LLC, Attn: Prospectus Department, 600 Montgomery Street, 10th Floor, San Francisco, CA 94111, by telephone: (415) 835-8985.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About Argos Therapeutics
Argos is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform.